Genmab (GMAB) and AbbVie (ABBV) announced the FDA granted priority review for the supplemental Biologics License Application, or sBLA, for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Genmab upgraded to Outperform from Market Perform at BMO Capital
